ClinicalTrials.gg
DrugRead study by study

Enfortumab vedotin clinical trials

Also written Padcev, ASG-22CE and AGS-22M6E.

studies test it
57
open now
34
in phase 3
7
first study started
2011
ClinicalTrials.gov finds 110 studies for enfortumab vedotin. How that becomes 57 here

Every study that search finds has been read, to see whether and how it gives enfortumab vedotin. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 110Found by its intervention search · See all 110 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 82 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −5
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 105Give enfortumab vedotin to participants
  4. −17Observe patients on it, or give it outside a trial
  5. −1Use it as a tool: an imaging tracer or a test of drug response
  6. −4Compare another treatment with it
  7. −26Give it beside what is tested
  8. 57Test it: the count on this site

Get an email when these change. Save the enfortumab vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
18 Dec 2019 · PADCEV · BLA 761137 (FDA, Drugs@FDA)
European Union
13 Apr 2022 · Padcev · EMEA/H/C/005392 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Enfortumab Vedotin
47
Anti-Nectin 4 ADC ASG-22CE
6
Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E
6
Enfortumab Vedotin-ejfv
6
enfortumab vedotin (EV)
5

Brand

Padcev
24

Development codes

ASG-22CE
19
AGS-22M6E
7
ASG-22ME
7
AGS 22ME
6
ASP7465
1

Studies by the year they started

56 studies that test it; most in 2026 (13); 1 more planned to start later

Studies that test enfortumab vedotin, by start year
YearStudies
20111
20141
20173
20181
20192
20202
20215
20224
20237
20245
202512
202613

By phase

A phase 1/2 study counts in both.

Phase 1
13
Phase 2
43
Phase 3
7
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 37

Astellas Pharma Global Development, Inc. (9) · National Cancer Institute (NCI) (3) · Memorial Sloan Kettering Cancer Center (3) · Merck Sharp & Dohme LLC (3) · Fox Chase Cancer Center (3) · Astellas Pharma Inc (3) · University of Utah (2) · Grupo Español Multidisciplinar de Melanoma (1)

Often tested with

Tested in the same studies.

Pembrolizumab (23) · Sacituzumab govitecan (5) · Trastuzumab deruxtecan (4) · Enfortumab Vedotin/Pembrolizumab Regimen (2) · Cisplatin (2) · Gemcitabine (2) · Niraparib (2) · Erdafitinib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Enfortumab vedotin is the comparator. A study of two new drugs counts under both.

New treatments tested with it · 8 most studied

New when their studies opened, with enfortumab vedotin beside them; studies of each.

Reaching primary completion within a year · 17

Studies that test enfortumab vedotin.

Studies

Open first, then newest update. How each study uses enfortumab vedotin has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 57

See all 57 studies that test enfortumab vedotin →

Tested on its own · 19 — no other medicine in its arm
Tested with established drugs · 4 — they are given beside it
Tested in a combination · 34 — another drug in the study is under test too

Showing 20 of 34. See all 34 →

Beside an established treatment under test · 5 — an approved drug, surgery or radiation is what the study tests

Tested with enfortumab vedotin: Surgery or a procedure 3 · nadofaragene firadenovec 1 · datopotamab deruxtecan 1 · olomorasib 1 · cabozantinib 1

Beside a new treatment under test · 14 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with enfortumab vedotin: sitravatinib 2 · vepugratinib 2 · sacituzumab govitecan 1 · zimberelimab 1 · domvanalimab 1 · intismeran autogene 1 · Favezelimab/Pembrolizumab Formulation 1 · Vibostolimab/Pembrolizumab MK-7684A 1

Beside supportive care · 5 — a supportive treatment or test is studied
One option of several · 2 — a test or a strategy chooses among drugs
As the comparator · 4 — what is tested is compared with enfortumab vedotin
Observed · 17 — patients on it are followed, or it is given outside a trial
As a tool · 1 — an imaging tracer or a test of drug response

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call enfortumab vedotin · ClinicalTrials.gg INT001132

  • MeSH (NLM) C000632577enfortumab vedotinConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) DLE8519RWMENFORTUMAB VEDOTINConfirmed FDA, NLM, Wikidata
  • RxNorm 2268306One source FDA
  • Wikidata Q19904068enfortumab vedotinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C114500Enfortumab VedotinOne source FDA
  • DrugBank DB13007One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion